A rare disease coalition calls on the Trump administration to appoint a new CBER director who understands rare disease drug development and values the views of patients and doctors.
An FDA untitled letter cautions the Fort Myers, FL-based LeeSar drug outsourcing facility about CGMP and other violations in its production of compounded drugs.
